8-K: Praxis Reports Strong Q2, Vormatrigine Shines in RADIANT Study

Praxis Precision Medicines announced positive topline results from its RADIANT study for vormatrigine in focal onset seizures, alongside its second quarter 2025 financial results, maintaining cash runway into 2028.

Summary

• Praxis Precision Medicines reported its second quarter 2025 financial results and provided a comprehensive corporate update.
• Topline results from the RADIANT study evaluating vormatrigine in patients with focal onset seizures (n=37) showed a 56.3% median reduction in seizure frequency from baseline over eight weeks.
• Approximately 22% of patients in the RADIANT study achieved 100% reduction in seizure frequency in the last 28 days, with about 60% achieving a 50% response.
• Vormatrigine was generally well-tolerated and demonstrated a favorable safety profile in the RADIANT study.
• Cash, cash equivalents, and marketable securities totaled $446.6 million as of June 30, 2025, a decrease from $469.5 million on December 31, 2024, but still projected to fund operations into 2028.
• The company reported a net loss of $71.1 million for the three months ended June 30, 2025, compared to a net loss of $32.7 million for the same period in 2024.
• Research and development expenses significantly increased to $63.0 million in Q2 2025 from $27.3 million in Q2 2024.
• Relutrigine received U.S. FDA Breakthrough Therapy Designation in July 2025 for the treatment of seizures associated with SCN2A and SCN8A Developmental and Epileptic Encephalopathies (DEEs).
• Praxis initiated two new registrational studies: EMERALD for broad DEEs with relutrigine and EMBRAVE3 for SCN2A Gain-of-Function (GoF) with elsunersen.
• Enrollment has been completed for both Phase 3 studies in the Essential 3 program for ulixacaltamide in Essential Tremor.

Sentiment

Score: 8

Explanation: The filing presents very strong positive clinical data for vormatrigine, positioning it as a potential best-in-class treatment for focal onset seizures, and highlights significant progress across other pipeline assets, including Breakthrough Therapy Designation for relutrigine. The extended cash runway into 2028 provides financial stability. While the net loss and R&D expenses increased, this is typical for a clinical-stage biopharmaceutical company advancing multiple programs, and the positive clinical outcomes and regulatory designations outweigh the increased burn rate for now.

Positives

• Vormatrigine's RADIANT study demonstrated strong efficacy with a 56.3% median reduction in seizure frequency and 22% of patients achieving 100% seizure reduction, indicating potential 'best-in-disease' efficacy.
• Vormatrigine exhibited a favorable safety and tolerability profile, with lower rates of adverse events compared to other modern anti-seizure medications.
• Relutrigine received FDA Breakthrough Therapy Designation for SCN2A and SCN8A DEEs, which is expected to expedite its development and regulatory process.
• Initiation of two new registrational studies (EMERALD and EMBRAVE3) signifies significant pipeline advancement and commitment to addressing unmet medical needs.
• Cash and investments of approximately $447 million as of June 30, 2025, provide a robust financial runway into 2028.
• The EMBOLD cohort 1 study group for relutrigine in SCN2A and SCN8A DEEs showed a ~90% reduction in seizures and a substantial increase in the mean period between seizures (from 3 to 67 days at month 11).

Negatives

• Net loss significantly increased to $71.1 million in Q2 2025 from $32.7 million in Q2 2024, reflecting higher operational costs.
• Research and development expenses more than doubled to $63.0 million in Q2 2025 from $27.3 million in Q2 2024, indicating increased burn rate.
• Cash, cash equivalents, and marketable securities decreased by $22.9 million from December 31, 2024, to June 30, 2025.
• No collaboration revenue was recognized in Q2 2025, compared to $0.4 million in Q2 2024, due to the conclusion of research service obligations with UCB.

Risks

• Uncertainties inherent in clinical trials, including the possibility that preliminary analyses may differ materially from final data.
• The expected timing of clinical trials, data readouts, and submissions for regulatory approval or review by governmental authorities are subject to change.
• The ability to obtain and maintain regulatory approval for any of the product candidates is not guaranteed.
• Other risks concerning the company's programs and operations are detailed in its Annual Report on Form 10-K for the year ended December 31, 2024, and Quarterly Report on Form 10-Q for the period ended June 30, 2025.

Future Outlook

Praxis expects to continue advancing its clinical programs, including initiating POWER2 and POWER3 studies for vormatrigine, completing enrollment for EMERALD and EMBOLD Cohort 2, and receiving topline results for ulixacaltamide in early fall 2025. The company also plans to nominate development candidates for its early-stage ASO therapeutic initiatives by mid-to-year-end 2025. Cash and investments are projected to fund operations into 2028.

Management Comments

• "In the second quarter, we continued to make remarkable progress across our portfolio and believe we are positioned to revolutionize treatment in both common and rare epilepsy."
• "Earlier today we reported the positive results from the RADIANT study, where vormatrigine has shown an impressive 56.3% reduction in seizures in 8 weeks in a heavily pre-treated population."
• "Enrollment is going well for the POWER1 pivotal study for vormatrigine, and we plan to shortly initiate POWER2 as well as the POWER3 study investigating vormatrigine as a standalone agent."
• "Our relutrigine program continues to progress strongly, first with the breakthrough therapy designation for SCN2A and SCN8A DEEs, which we expect will allow us to expedite the regulatory process, and second with the initiation of the EMERALD registrational study in broad DEEs."
• "Completing our progress across epilepsy, we also initiated the registrational EMBRAVE3 study of elsunersen in SCN2A patients."
• "We remain well-capitalized as we look ahead to an exciting second half of 2025."

Industry Context

The company is focused on central nervous system (CNS) disorders, particularly epilepsy and movement disorders, addressing a significant unmet need for new, tolerable, fast-acting, and durable therapies for focal onset seizures, which affect approximately 3 million patients in the U.S. The development of precision sodium-channel modulators and antisense oligonucleotides (ASOs) targets specific genetic drivers, positioning Praxis to potentially revolutionize treatment in both common and rare epilepsies.

Comparison to Industry Standards

• Vormatrigine's 56.3% median reduction in seizure frequency and 22% 100% reduction rate in the RADIANT study are presented as 'Best-in-Disease Efficacy' compared to other anti-seizure medications (ASMs).
• Vormatrigine's safety profile (59% patients with >=1 TEAE, 4.9% severe AEs, 4.9% SAEs, 1.6% related SAE) is positioned as 'best-in-disease ASM' with lower rates of TEAEs and CNS AEs compared to Cenobamate (90% TEAEs, 16% severe AEs, 7% SAEs) and XEN1101 (85% TEAEs, 2.6% SAEs).
• Vormatrigine's once-daily dosing, no titration, and no expected restrictions with concomitant ASMs or common contraceptive agents are highlighted as an 'ideal dosing profile' compared to Cenobamate (12-week titration) and XEN1101 (evening dosing with food, significant DDIs).
• The company notes that 30% of RADIANT patients were on cenobamate, described as the 'most challenging ASM background to demonstrate effect in any focal epilepsy study,' suggesting strong performance in a difficult-to-treat patient population.

Stakeholder Impact

• Shareholders: Positive clinical trial results and an extended cash runway could increase investor confidence and potentially lead to share price appreciation. However, increased net loss and R&D expenses indicate a higher burn rate.
• Patients (Epilepsy/Tremor): Promising new treatment options (vormatrigine, relutrigine, elsunersen, ulixacaltamide) with potential for improved efficacy and safety profiles. Breakthrough Therapy Designation for relutrigine could expedite patient access.
• Employees: Continued progress in clinical development and a stable financial outlook suggest job security and potential for company growth.

Next Steps

• Present additional RADIANT study data at the 36th International Epilepsy Congress on August 31, 2025, in Lisbon, Portugal.
• Present full RADIANT study results at the American Epilepsy Society Annual Meeting in December 2025, in Atlanta, Georgia.
• Initiate the POWER2 Phase 2/3 registrational study for focal onset seizures in the third quarter of 2025.
• Complete enrollment for the POWER1 Phase 2/3 registrational study for focal onset seizures in the fourth quarter of 2025.
• Initiate the POWER3 study to evaluate vormatrigine as a standalone agent in the first half of 2026.
• Expect topline results for the EMBOLD Cohort 2 (SCN2A GoF and SCN8A) no later than the first half of 2026, followed by a potential NDA submission.
• Complete enrollment for the EMERALD registrational study in broad DEEs in 2026.
• Expect topline results for ulixacaltamide Phase 3 studies (Essential 3 program) in early fall 2025, after which the company will determine if there is sufficient evidence for an NDA submission.
• Expect topline results for the EMBRAVE Part A Phase 1/2 study (elsunersen) in the first half of 2026.
• Nominate a development candidate for PRAX-080 (targeting PCDH19 mosaic expression disorder) by year-end 2025.
• Nominate a development candidate for PRAX-090 (targeting SYNGAP1 loss-of-function mutations) by year-end 2025.
• Nominate a development candidate for PRAX-100 (targeting SCN2A LoF mutations) by mid-2025.

Key Dates

Recommendation

The positive topline results from the RADIANT study for vormatrigine, demonstrating significant seizure reduction and a favorable safety profile, are highly encouraging and position it as a potential best-in-class therapy. The FDA Breakthrough Therapy Designation for relutrigine further de-risks and accelerates another key pipeline asset. With multiple registrational studies initiated and a cash runway extending into 2028, the company is well-capitalized to advance its diverse CNS portfolio. Despite increased R&D expenses and net loss, these are expected for a company with such active and promising clinical development, and the strong clinical data and strategic progress suggest significant upside potential.

Keywords

Epilepsy, Seizures, Vormatrigine, RADIANT study, Relutrigine, DEE, SCN2A, SCN8A, Elsunersen, Ulixacaltamide, Essential Tremor, Biopharmaceutical, Clinical-stage, CNS disorders, Praxis Precision Medicines, PRAX